Evidence-Supported Indications Adults with BMI 35 kg/m, or BMI 27 with at least one or more weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea Type 2 Diabetes: Adults requiring improved glycemic control this remains the foundation of the drug class and where the longest safety record exists Cardiovascular Risk Reduction: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease Metabolic Syndrome Presentations: Patients with non-alcoholic fatty liver disease, polycystic ovarian syndrome, and insulin resistance syndromes Binge Eating Disorder (BED) Emerging Data: Emerging evidence suggests GLP-1 medications may reduce binge frequency though this data remains preliminary and is discussed in detail below Why It Is Not "Cheating" The genetics of obesity are increasingly well-characterized
Pricing pressure
Exp Dermatol (2014) 23(6):4313
Like GHRP-6 and ipamorelin, MK-677 can cross the blood-brain barrier to activate the pituitary gland's ghrelin receptors, leading to GH release
It helps regulate innate immunity and protects against infection, including parasitic, microbial, and viral diseases
Approximately 25% of total weight loss typically originates from fat-free mass, with skeletal muscle comprising about half of this component [29]